Skip to main content

Table 1 Characteristics of patients and first AE reported according to age group at onset of biological therapy

From: Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register

VariablesYoungAdultElderlyVery Elderlyp
N = 248363212723756 
Age, mean (SD) in years21.48 (4.48)47.91 (9.98)69.12 (2.87)78.81 (3.10) 
Female gender (%)25 (39.68)1163 (54.68)171 (72.159)42 (75.09)< 0.001
Disease duration, mean (SD) in years2.72 (3.39)7.28 (7.68)9.46 (9.40)8.19 (8.95)< 0.001
Duration of biologic treatment, mean (SD) in years3.12 (3.409)2.60 (3.14)1.79 (2.18)1.57 (1.95)< 0.001
Diagnosis,n(%)
 RA, n = 112613 (1.15)903 (80.20)161 (14.30)49 (4.35)< 0.001
 PsA, n = 68035 (5.15)610 (89.71)32 (4.71)3 (0.44)
 AS, n = 67715 (2.22)614 (90.69)44 (6.50)4 (0.59)
Comorbidities
 Charlson Index, mean (SD)1.02 (0.13)1.25 (0.68)1.81 (1.49)2.07 (1.41)< 0.001
 Tobacco: smokers/past smokers, n (%)15 (23.81)645 (30.32)64 (27.00)7 (12.50)0.047
Concomitant immunosuppressive treatment,n(%) of use
 MTX23 (41.8)943 (53.61)106 (55.79)27 (60.00)0.243
 Corticosteroids15 (27.78)806 (46.51)129 (64.18)33 (71.74)< 0.001
 Initial corticoids dose (mg/day)15.55 (16.26)8.29 (7.24)8.03 (5.85)8.03 (6.37)0.011
 Other8 (12.70)627 (29.48)83 (35.02)23 (41.07)0.002
First AE (Total),n(%)33 (52.4)1227 (57.7)147 (62.0)37 (66.1) 
 Infections9 (27.27)391 (31.87)50 (34.01)11 (29.73)0.789
 Traumatic injuries2 (6.06)104 (8.48)14 (9.52)3 (8.11)
 Neoplasms0 (0.00)28 (2.28)6 (4.08)1 (2.70)
 Skin disorders5 (15.15)131 (10.68)15 (10.20)1 (2.70)
 Others17 (51.52)573 (46.70)62 (42.18)21 (56.76)
First severe AE,n(%)4 (6.3)138 (6.5)36 (15.2)11 (19.6) 
 Infections1 (25.00)45 (32.61)13 (36.11)1 (9.09)0.052
 Traumatic injuries0 (0.00)9 (6.52)2 (5.56)1 (9.09)
 Neoplasms0 (0.00)17 (12.32)3.8 (8.33)0 (0.00)
 Skin disorders0 (0.00)0 (0.00)0 (0.00)1 (9.09)
 Others3 (75.00)67 (48.55)18 (50.00)8 (72.73)
No AEn(%)30 (47.6)900 (42.3)90 (38.0)19 (33.9) 
  1. AS ankylosing spondylitis, MTX methotrexate, PsA psoriatic arthritis, RA rheumatoid arthritis, TNF-i tumor necrosis factor inhibitor